Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT Dosing for Mild to Moderate Ulcerative Colitis
NCT03006809Phase 1Completed
- Start
- Mar 2017
- Primary completion
- May 2020
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Fecal Microbiota Transplantation Capsule in ulcerative colitis (UC) (4 arms). Primary endpoints: Serious Adverse Events at 1 year and Steroid-free Clinical Remission at 9 weeks. Started Mar 2017; status: completed.
02
Drugs
Fecal Microbiota Transplantation Capsule
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03006809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03006809.